RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

被引:131
|
作者
Wen, Patrick Y. [1 ,2 ]
van den Bent, Martin [3 ]
Youssef, Gilbert [1 ,2 ]
Cloughesy, Timothy F. [4 ]
Ellingson, Benjamin M. [5 ]
Weller, Michael [6 ,7 ]
Galanis, Evanthia [8 ]
Barboriak, Daniel P. [9 ]
de Groot, John [10 ]
Gilbert, Mark R. [11 ]
Huang, Raymond [2 ,12 ]
Lassman, Andrew B. [13 ,14 ,15 ]
Mehta, Minesh [16 ]
Molinaro, Annette M. [17 ]
Preusser, Matthias [18 ]
Rahman, Rifaquat [19 ]
Shankar, Lalitha K. [20 ]
Stupp, Roger [21 ,22 ,23 ,24 ]
Villanueva-Meyer, Javier E. [25 ,26 ]
Wick, Wolfgang [27 ,28 ]
Macdonald, David R. [29 ,30 ]
Reardon, David A. [1 ,2 ]
Vogelbaum, Michael A. [31 ,32 ]
Chang, Susan M. [10 ]
机构
[1] Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands
[4] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Tumor Program, Los Angeles, CA USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, UCLA Brain Tumor Imaging Lab, Los Angeles, CA USA
[6] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland
[7] Univ Zurich, Zurich, Switzerland
[8] Mayo Clin, Dept Oncol, Rochester, MN USA
[9] Duke Univ, Med Ctr, Dept Radiol, Durham, NC USA
[10] Univ Calif San Francisco, Dept Neurosurg, Div Neurooncol, San Francisco, CA USA
[11] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[12] Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA
[13] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurol,Div Neuroradiol, New York, NY USA
[14] Columbia Univ, Irving Inst Clin & Translat Res, Vagelos Coll Phys & Surg, New York, NY USA
[15] New York Presbyterian Hosp, New York, NY USA
[16] Miami Canc Inst, Miami, FL USA
[17] Univ Calif San Francisco, Dept Neurol Surg, Div Biomed Stat & Informat, San Francisco, CA USA
[18] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria
[19] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA
[20] NCI, Clin Trials Branch, Canc Imaging Program, NIH, Bethesda, MD USA
[21] Northwestern Univ, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr, Chicago, IL USA
[22] Northwestern Univ, Dept Neurol Surg, Chicago, IL USA
[23] Northwestern Univ, Dept Neurol, Chicago, IL USA
[24] Northwestern Univ, Div Hematol Oncol, Chicago, IL USA
[25] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[26] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA
[27] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany
[28] German Canc Res Ctr, ClinicalCooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany
[29] Western Univ, Dept Clin Neurol Sci, London, ON, Canada
[30] Western Univ, Dept Oncol, London, ON, Canada
[31] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA
[32] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, Tampa, FL USA
关键词
MALIGNANT GLIOMA; GLIOBLASTOMA; PSEUDOPROGRESSION; PROGRESSION; RECOMMENDATIONS; RECIST; PET;
D O I
10.1200/JCO.23.01059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEThe Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria.METHODSInformed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0).RESULTSWe recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment.CONCLUSIONThe revised RANO 2.0 criteria refine response assessment in gliomas.
引用
收藏
页码:5189 / +
页数:15
相关论文
共 50 条
  • [31] NEURO-ONCOLOGY Late neurocognitive decline after radiotherapy for low-grade glioma
    Khasraw, Mustafa
    Lassman, Andrew B.
    NATURE REVIEWS NEUROLOGY, 2009, 5 (12) : 646 - 647
  • [32] Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative
    Dirven, Linda
    Armstrong, Terri S.
    Blakeley, Jaishri O.
    Brown, Paul D.
    Grant, Robin
    Jalali, Rakesh
    Leeper, Heather
    Mendoza, Tito
    Nayak, Lakshmi
    Reijneveld, Jaap C.
    Le Rhun, Emilie
    Walbert, Tobias
    Weller, Michael
    Wen, Patrick Y.
    Taphoorn, Martin J. B.
    LANCET ONCOLOGY, 2018, 19 (03): : E173 - E180
  • [33] Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2014, 16 (03) : 329 - 329
  • [34] Brain location and tumor biological markers in high- and low-grade gliomas
    Dehcordi, Soheila Raysi
    Galzio, Renato
    Marrone, Federica
    Di Vitantonio, Hambra
    Marzi, Sara
    Fasano, Teresa
    Taddei, Graziano
    Millimaggi, Daniele
    Di Cosimo, Tonino
    Abbate, Francesco
    Calvisi, Giuseppe
    Masciocchi, Carlo
    Ricci, Alessandro
    JOURNAL OF NEUROSURGICAL SCIENCES, 2023, 67 (02) : 143 - 149
  • [35] Measurable Disease in Glioblastoma using PET-based Response Assessment in Neuro-Oncology (PET RANO 1.0)
    Harlianto, Netanja i.
    RADIOLOGY-IMAGING CANCER, 2025, 7 (01):
  • [36] RESPONSE ASSESSMENT IN PEDIATRIC HIGH-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY WORKING GROUP
    Erker, Craig
    Tamrazi, Benita
    Poussaint, Tina Y.
    Mueller, Sabine
    Mata-Mbemba, Daddy
    Franceschi, Enrico
    Brandes, Alba A.
    Rao, Arvind
    Haworth, Kellie B.
    Wen, Patrick Y.
    Goldman, Stewart
    Vezina, Gilbert
    Macdonald, Tobey J.
    Dunkel, Ira J.
    Morgan, Paul S.
    Jaspan, Tim
    Prados, Michael D.
    Warren, Katherine E.
    NEURO-ONCOLOGY, 2020, 22 : 355 - 355
  • [38] LOW GRADE GLIOMAS TREATED IN A UNIVERSITY-BASED COMBINED NEURO-ONCOLOGY SERVICE IN SOUTH AFRICA
    Davidson, Alan
    Figaji, Anthony
    Pillay, Komala
    Kilborn, Tracy
    Padayachy, Llewellyn
    Hendricks, Marc
    van Eyssen, Ann
    Parkes, Jeannette
    NEURO-ONCOLOGY, 2014, 16 : 68 - 68
  • [39] Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG)
    Costanza Papagno
    Alessandra Casarotti
    Alessandro Comi
    Marcello Gallucci
    Marco Riva
    Lorenzo Bello
    Journal of Neuro-Oncology, 2012, 108 : 269 - 275
  • [40] NEUROLOGICAL ASSESSMENT IN NEURO-ONCOLOGY (NANO) CORRELATES WITH INTEGRATED PREDICTIVE RADIOGRAPHIC BIOMARKERS OF PROGRESSED HIGH GRADE ASTROCYTIC TUMORS (IPROMPT): A PROPOSED SUPPLEMENT TO RANO
    Gatson, Na Tosha
    Bross, Shane
    Lockard, Laura
    Leese, Erika
    Manikowski, Jesse
    Mahadevan, Anand
    Conger, Andrew
    Mongelluzzo, Gino
    NEURO-ONCOLOGY, 2019, 21 : 178 - 178